EAM
MRSN

Empirical Asset Management’s Mersana Therapeutics MRSN Stock Holding History

Empirical Asset Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-400
Closed -$12.7K – 200
2023
Q3 		$12.7K Hold
400
– – 0.01% 165
2023
Q2 		$32.9K Hold
400
– – 0.03% 154
2023
Q1 		$41.1K Hold
400
– – 0.04% 144
2022
Q4 		$58.6K Hold
400
– – 0.06% 151
2022
Q3 		$68K Hold
400
– – 0.07% 143
2022
Q2 		$46K Hold
400
– – 0.05% 150
2022
Q1 		$40K Hold
400
– – 0.04% 144
2021
Q4 		$62K Buy
+400
New +$77.8K 0.06% 149

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Empirical Asset Management's MRSN Position: Q4 2023 in Review

Empirical Asset Management sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 400 shares — an estimated $12.7K sold.

Empirical Asset Management first reported a position in MRSN in Q4 2021 and held it in 8 quarters. The position peaked at $68K in Q3 2022. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • Empirical Asset Management reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Empirical Asset Management sold 400 Mersana Therapeutics shares in Q4 2023, an estimated $12.7K.
  • Empirical Asset Management first reported a position in Mersana Therapeutics in Q4 2021 and held it in 8 quarters.
  • Empirical Asset Management's Mersana Therapeutics position peaked at $68K in Q3 2022.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on Empirical Asset Management's 13F filing for Q4 2023, filed 12 Jan 2024.